Latest News of ANVS
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders
By Yahoo! Finance |
1 month ago
Retail investors own a majority stake of 56% in Annovis Bio, giving them significant influence over management decisions. Institutional investors also hold a portion, indicating confidence in the comp...
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History
By Yahoo! Finance |
3 months ago
Annovis Bio is a drug platform company working on treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. They have lead candidates in various stages of clinical trials, aiming to ...
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
3 months ago
Annovis Bio's Phase III Parkinson's study shows promising results with buntanetap treatment, leading to improvements in UPDRS and cognition....
-
ANVS Stock Price | Annovis Bio Inc. Stock Quote (U.S.: NYSE) | MarketWatch
By MarketWatch | 3 months agoAnnovis Bio, Inc. is a drug platform company developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead candidate, Buntanetap, targets AD, PD, and other neurodeg...